PMID- 21109925
OWN - NLM
STAT- MEDLINE
DCOM- 20110524
LR  - 20101126
IS  - 1791-2423 (Electronic)
IS  - 1019-6439 (Linking)
VI  - 38
IP  - 1
DP  - 2011 Jan
TI  - Tumor localization of an anti-TGF-beta antibody and its effects on gliomas.
PG  - 51-9
AB  - Even with current standard-of-care therapies, the prognosis for patients with 
      malignant gliomas is very poor and several new treatment modalities for 
      glioblastomas are currently under investigation. Given the role of TGF-beta in 
      gliomas, anti-TGF-beta strategies against gliomas are currently being investigated. 
      Biodistribution of intravenously injected AF680-labeled 1D11, a pan-neutralizing 
      TGF-beta antibody, was monitored in mice bearing either subcutaneous or orthotopic 
      gliomas using in vivo imaging and fluorescence microscopy. AF680-labeled 1D11 
      entered both the subcutaneous and intracranial tumors and the antibody was 
      detected within the tumor tissue for several days whereas only low fluorescence 
      was found in organs. The effects of 1D11 on subcutaneous versus orthotopic U87MG 
      and GL261 gliomas in immunocompetent C57BL/6J versus immunodeficient CD1-Foxn1nu 
      mice were observed by direct tumor size measurement, H&E staining and 
      immunohistochemistry. Treatment of immunocompetent mice bearing subcutaneous 
      GL261 tumors with 1D11 resulted in complete remission. In immune deficient mice, 
      the growth of subcutaneous GL261 tumors was increased following treatment with 
      1D11. Intracranially implanted gliomas in C57Bl/6J mice showed no size reduction 
      after 1D11 treatment but there was reduced invasion of the glioma cells into the 
      adjacent normal brain. Together these data demonstrate that TGF-beta plays different 
      roles in combating the tumor depending on subcutaneous versus orthotopic 
      implantation site.
FAU - Hulper, Petra
AU  - Hulper P
AD  - Department of Pediatrics I, University Medical Center Gottingen, Robert-Koch-Str. 
      40, D-37099 Gottingen, Germany. huelper@med.uni-goettingen.de
FAU - Schulz-Schaeffer, Walter
AU  - Schulz-Schaeffer W
FAU - Dullin, Christian
AU  - Dullin C
FAU - Hoffmann, Peter
AU  - Hoffmann P
FAU - Harper, Jay
AU  - Harper J
FAU - Kurtzberg, Leslie
AU  - Kurtzberg L
FAU - Lonning, Scott
AU  - Lonning S
FAU - Kugler, Wilfried
AU  - Kugler W
FAU - Lakomek, Max
AU  - Lakomek M
FAU - Erdlenbruch, Bernhard
AU  - Erdlenbruch B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Transforming Growth Factor beta)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/immunology/pharmacokinetics/*pharmacology
MH  - Antibody Specificity
MH  - Brain Neoplasms/*drug therapy/immunology/pathology
MH  - Cell Line, Tumor
MH  - Glioma/*drug therapy/immunology/pathology
MH  - Humans
MH  - Immunocompetence
MH  - Immunohistochemistry
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Nude
MH  - Microscopy, Fluorescence
MH  - Neoplasm Invasiveness
MH  - Spectroscopy, Near-Infrared
MH  - Tissue Distribution
MH  - Transforming Growth Factor beta/*immunology
MH  - Xenograft Model Antitumor Assays
EDAT- 2010/11/27 06:00
MHDA- 2011/05/25 06:00
CRDT- 2010/11/27 06:00
PHST- 2010/11/27 06:00 [entrez]
PHST- 2010/11/27 06:00 [pubmed]
PHST- 2011/05/25 06:00 [medline]
PST - ppublish
SO  - Int J Oncol. 2011 Jan;38(1):51-9.